Advertisement
News
Subscribe to MDT Magazine News

TriReme Medical Announces $17 Million Series D Financing

October 11, 2010 5:34 am | by Bio-Medicine.Org | Comments

PLEASANTON, Calif., Oct. 11 /- TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing.  The financing was led by Bio*One Capital, a subsidiary of Singapore based...

TOPICS:

Varian Medical Systems and Stanford University Win $3.6 Million Five-Year NIH/NCI Research Grant to Develop Advanced Imaging Technology

October 11, 2010 5:33 am | by Bio-Medicine.Org | Comments

PALO ALTO, Calif., Oct. 11 /- Scientists from Stanford University and from the Ginzton Technology Center at Varian Medical Systems have jointly received a $3.6 million five-year research grant from the U.S. National Institutes of Health (NIH) to develop advanced imaging technology...

TOPICS:

Chongqing Cancer Hospital Becomes First Hospital in Southwest China to Offer Cancer Patients Fast, Precise Treatment Using RapidArc® Radiotherapy from Varian Medical Systems

October 11, 2010 5:33 am | by Bio-Medicine.Org | Comments

BEIJING, and PALO ALTO, Calif., Oct. 11 /- Chongqing Cancer Hospital in Southwest China has become the first treatment center in Southwest China to offer cancer patients a faster, more precise form of image-guided radiotherapy that potentially enables doctors to improve outcomes while...

TOPICS:
Advertisement

MuGard Provides Significant Improvement or Stabilization of Oral Mucositis in Over 75% of Patients in European Clinical Experience

October 11, 2010 5:33 am | by Bio-Medicine.Org | Comments

DALLAS and NEW YORK, Oct. 11 /- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP ), a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's...

TOPICS:

DATATRAK Awarded Three Phase III Studies

October 11, 2010 5:33 am | by Bio-Medicine.Org | Comments

CLEVELAND, Oct. 11 /- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of an Enterprise Agreement for three new Phase III oncology studies with an existing...

TOPICS:

DePuy Orthopaedics Accused of Deceiving Hip Replacement Patients

October 11, 2010 5:32 am | by Bio-Medicine.Org | Comments

CLEVELAND, Oct. 11 /- The preeminent law office of Nurenberg, Paris, Heller & McCarthy has filed a class action lawsuit against Johnson & Johnson's artificial joint replacement company DePuy Orthopaedics, Inc., on behalf of clients who suffered damages resulting from the company's...

TOPICS:

IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery

October 11, 2010 5:32 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., Oct. 11 /- IRIDEX Corporation (Nasdaq: IRIX ) today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery. The Adjustable & Intuitive Laser...

TOPICS:

Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA

October 11, 2010 5:31 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, Oct. 11 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) announced today that Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug...

TOPICS:
Advertisement

Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronie's Disease

October 11, 2010 4:31 am | by Bio-Medicine.Org | Comments

MALVERN, Pa., Oct. 11 /- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ), a specialty biopharmaceutical company, today announced that the first subject has been dosed in the global phase III program of XIAFLEX® for the treatment of Peyronie's disease.  Peyronie's disease is the...

TOPICS:

Maturing MEMS sector moves towards common testing protocols

October 11, 2010 12:32 am | by I-Micronews | Comments

By Paula Doe, SEMI Emerging Markets

Roche and German Cancer Research Center (DKFZ) Enter Research Agreement to Predict Cervical Cancer

October 11, 2010 12:32 am | by Bio-Medicine.Org | Comments

PLEASANTON, Calif., Oct. 11 /- Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) and the German Cancer Research Center (DKFZ) announced today that they have entered into a research collaboration to enable more specific prediction of a woman's risk for developing cervical cancer....

TOPICS:

Reform Brings Healthy Outlook for Improved Access to Alternative Care

October 11, 2010 12:31 am | by San Diego Business Journal | Comments

Alternative and ancillary health care professionals are hopeful that the federal health care reform legislation that recently began taking effect will improve access to all types of effective treatment and therapies.

TOPICS:

Executive Profile

October 10, 2010 11:31 pm | by San Diego Business Journal | Comments

Bradley A. Marcus, a doctor of osteopathic medicine, is the founder and operator of Medical Rehabilitation & Kinematics Lab. He is board-certified by the American Board of Medical Specialties in the field of physical medicine and rehabilitation.

TOPICS:

Oral Delivery System Developed to Treat Inflammatory Bowel Diseases

October 10, 2010 3:32 pm | by Georgia Tech Institute of Technology | Comments

Researchers have developed a novel approach for delivering genetic material into the body to improve the treatment of inflammatory bowel diseases.

Lipitor (atorvastatin) 40 mg: Recall specific bottles

October 10, 2010 12:30 pm | by U.S. Food & Drug Administration | Comments

Specific bottles of Lipitor 40 mg recalled due to a small number of reports of an uncharacteristic odor.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading